MedTrace Logo

Omega-3 Fatty Acids Supplementation in ADHD

NCT01777048 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-06-24

No results posted yet for this study

Summary

The overarching aim of the proposed study is to assess whether omega-3 fatty acids supplementation can augment the effects of methylphenidate in children with ADHD. The investigators hypothesized that omega-3 fatty acids supplementation will be associated with improved ADHD symptoms.

Conditions

  • ADHD

Interventions

DIETARY_SUPPLEMENT

Omega-3 Fatty Acids Supplementation

DIETARY_SUPPLEMENT

Omega-3 Placebo

Placebo capsules manufactured to mimic Omega-3 capsules

Sponsors & Collaborators

  • Universitäre Psychiatrische Kliniken (UPK) Basel

    collaborator UNKNOWN

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Yoon Phaik Ooi, PhD · University of Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777048 on ClinicalTrials.gov